These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 6364709)
1. Haemodynamic and antihypertensive effect of prostacyclin. Szczeklik A; Gryglewski RJ; Szczeklik J; Nizankowski R Adv Exp Med Biol; 1984; 164():299-305. PubMed ID: 6364709 [No Abstract] [Full Text] [Related]
2. Epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. Botney M N Engl J Med; 1998 Jun; 338(24):1773-4. PubMed ID: 9625639 [No Abstract] [Full Text] [Related]
3. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. Nicolas LB; Krause A; Gutierrez MM; Dingemanse J Br J Clin Pharmacol; 2012 Dec; 74(6):978-89. PubMed ID: 22515646 [TBL] [Abstract][Full Text] [Related]
4. Is prostacyclin an inodilator? Ricksten SE Intensive Care Med; 2003 Sep; 29(9):1403-5. PubMed ID: 12904857 [No Abstract] [Full Text] [Related]
5. The effect of prostacyclin on the gastric mucosa in portal-hypertensive rats. Kishihara F; Hashizume M; Ohta M; Kawanaka H; Tomikawa M; Higashi H; Tanoue K; Sugimachi K Hepatogastroenterology; 2002; 49(43):279-84. PubMed ID: 11941975 [TBL] [Abstract][Full Text] [Related]
6. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. McLaughlin VV; Genthner DE; Panella MM; Rich S N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Chaumais MC; Jobard M; Huertas A; Vignand-Courtin C; Humbert M; Sitbon O; Rieutord A; Montani D Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1587-98. PubMed ID: 21077785 [TBL] [Abstract][Full Text] [Related]
8. The renal haemodynamic and excretory actions of prostacyclin (PGI2) in anaesthetized dogs [proceedings]. Hill TW; Moncada S Br J Pharmacol; 1978 Mar; 62(3):413P-414P. PubMed ID: 346131 [No Abstract] [Full Text] [Related]
9. Effect of prostacyclin on gastric mucosal RNA-content in the rat. Balint GA Exp Toxicol Pathol; 1999 May; 51(3):207-8. PubMed ID: 10334459 [TBL] [Abstract][Full Text] [Related]
10. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287 [TBL] [Abstract][Full Text] [Related]
11. Managing patients with primary pulmonary hypertension: prostacyclin therapy. Albert NM; Hague K Am J Crit Care; 1997 Jul; 6(4):274-80. PubMed ID: 9215424 [No Abstract] [Full Text] [Related]
12. Systemic levels of 6-keto-prostaglandin F1 alpha following administration of inhaled aerosolized prostacyclin. van Heerden PV Anaesth Intensive Care; 1997 Dec; 25(6):701-3. PubMed ID: 9452859 [TBL] [Abstract][Full Text] [Related]
13. Haemodynamic changes induced by prostacyclin in man. Szczeklik J; Szczeklik A; Nizankowski R Br Heart J; 1980 Sep; 44(3):254-8. PubMed ID: 7000101 [TBL] [Abstract][Full Text] [Related]